Peptides have been prevalent as biopharmaceutical entities since the past twenty years but have come into focus only in the last five to six years due to improvements in manufacturing processes and delivery technologies. This research service aims to provide a strategic picture of therapeutic peptides from a research and development portfolio perspective and delineate the most critical criteria to be considered during evaluation of R&D portfolio projects. Using the current research scenario, market potential data and technical features of peptide drugs as tools, it provides a decision-making base for stakeholders at all stages in this industrial sector from small biotechnology companies to big pharmaceutical organizations.